Hepatitis A - hepatitis B vaccine - Sinovac Biotech

Drug Profile

Hepatitis A - hepatitis B vaccine - Sinovac Biotech

Alternative Names: Bilive; Bilive Adult; Bilive Junior; Combined hepatitis A and B vaccine - Sinovac Biotech

Latest Information Update: 06 Apr 2005

Price : $50

At a glance

  • Originator Sinovac Biotech
  • Class Hepatitis A vaccines; Hepatitis B vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatitis A; Hepatitis B

Most Recent Events

  • 31 Mar 2005 Launched for Hepatitis B prevention in China (Parenteral); first global launch
  • 31 Mar 2005 Launched for Hepatitis A prevention in China (Parenteral); first global launch
  • 12 Jan 2005 Registered for Hepatitis B prevention in China (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top